Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection a
Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis.
Drug Discovery📍 Shanghai, ChinaFounded 2013
Current Valuation
$604M
as of 2021-Q1
PRIVATE
QL Price
$604M
0% vs last round
QuantLogix's current estimate for ArkBio, published 2026-09-27 — in line with the last disclosed round of $604M (2021-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$604M
2021-Q1
weight 0.02
How this price has held up
No round has priced for ArkBio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, ArkBio, 2026-09-27 (c21e50590420359a).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is ArkBio going public?
No. ArkBio is private and has not filed to go public. There is no S-1 on file.
What is ArkBio's valuation in 2026?
ArkBio is valued at $604M as of 2021-Q1, set by its Series C1 ($86M, Jan 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has ArkBio filed an S-1?
No public S-1 is on file for ArkBio.
How much has ArkBio raised?
ArkBio has raised $210.78M in total, most recently a Series C1 of $86M in Jan 2021.
Is ArkBio publicly traded — can you buy ArkBio stock?
No. ArkBio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for ArkBio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2013
HQ
Shanghai, China
Employees
89
Total Raised
$210.78M
Last Round
Series C1 — $86M (Jan 2021)
IPO Status
private
Fundraising Status
Series C1 · $86M · 5y 8mo ago
privateTotal raised $210.78M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C1
$86M
Jan 2021
—
$604M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for ArkBio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for ArkBio as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
MedicalBiotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q1. Refreshed quarterly.